Gene · 338413
Papers2,372
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,372
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| mTOR activity paces human blastocyst stage developmental progression. | Cell | 2024 | 39332412 | PubTator, text mining | PubMed |
| JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results. | Blood | 2024 | 39046783 | PubTator, text mining | PubMed |
| Alpha-synuclein shapes monocyte and macrophage cell biology and functions by bridging alterations of autophagy and inflammatory pathways. | Front Cell Dev Biol | 2024 | 39035028 | PubTator, text mining | PubMed |
| Leucine-Mediated SLC7A5 Promotes Milk Protein and Milk Fat Synthesis through mTOR Signaling Pathway in Goat Mammary Epithelial Cells. | J Agric Food Chem | 2024 | 38807030 | PubTator, text mining | PubMed |
| PTEN and P-4E-BP1 might be associated with postoperative recurrence of rectal cancer patients undergoing concurrent radiochemotherapy. | BMC Cancer | 2024 | 38741069 | PubTator, text mining | PubMed |
| SuperCellCyto: enabling efficient analysis of large scale cytometry datasets. | Genome Biol | 2024 | 38589921 | PubTator, text mining | PubMed |
| The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features. | J Pathol Clin Res | 2024 | 38563252 | PubTator, text mining | PubMed |
| JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature. | Cancers (Basel) | 2024 | 38473222 | PubTator, text mining | PubMed |
| Kidney double positive T cells have distinct characteristics in normal and diseased kidneys. | Sci Rep | 2024 | 38396136 | PubTator, text mining | PubMed |
| Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells. | Cells | 2024 | 38391917 | PubTator, text mining | PubMed |
| EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. | Int J Mol Sci | 2024 | 38279277 | PubTator, text mining | PubMed |
| Transformation of an odontogenic keratocyst into a solid variant of odontogenic keratocyst/keratoameloblastoma during long‑term follow‑up: A case report. | Mol Med Rep | 2024 | 38275130 | PubTator, text mining | PubMed |
| Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. | NPJ Precis Oncol | 2024 | 38273040 | PubTator, text mining | PubMed |
| Combination of blockade of endothelin signalling and compensation of IGF1 expression protects the retina from degeneration. | Cell Mol Life Sci | 2024 | 38252153 | PubTator, text mining | PubMed |
| Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. | Sci Adv | 2024 | 38241371 | PubTator, text mining | PubMed |
| Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment. | PeerJ | 2024 | 38239299 | PubTator, text mining | PubMed |
| Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth. | Mol Cancer Ther | 2024 | 38224565 | PubTator, text mining | PubMed |
| Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells. | Nat Commun | 2024 | 38212337 | PubTator, text mining | PubMed |
| Commercial provider staff experiences of the NHS low calorie diet programme pilot: a qualitative exploration of key barriers and facilitators. | BMC Health Serv Res | 2024 | 38200539 | PubTator, text mining | PubMed |
| A new physiological medium uncovers biochemical and cellular alterations in Lesch-Nyhan disease fibroblasts. | Mol Med | 2024 | 38172668 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/338413/papers?page=4